Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Politics

Soaring Medicare prescription drug prices targeted in Trump’s new executive order

by admin April 16, 2025
April 16, 2025
Soaring Medicare prescription drug prices targeted in Trump’s new executive order

President Donald Trump is seeking to combat soaring prescription drug prices in a new executive order he signed Tuesday. 

The order instructs Robert F. Kennedy Jr.’s Department of Health and Human Services (DHS) to standardize Medicare payments for prescription drugs — including those used for cancer patients — no matter where a patient receives treatment. This could lower prices for patients by as much as 60%, according to a White House fact sheet.

Likewise, the order also calls to match the Medicare payment for certain prescription drugs to the price that hospitals pay for those drugs — up to 35% lower than what the government pays to acquire those medications, the White House said. 

The order also takes steps to lower insulin prices. Specifically, the order calls for lowering insulin prices for low-income patients or those that are uninsured to as little as three cents, and injectable epinephrine to treat allergic reactions to as low as $15, coupled with a ‘small administrative fee,’ according to a White House fact sheet. 

Additionally, the order attempts to drive down states’ drug prices by ‘facilitating importation programs that could save states millions in prescription drug prices,’ as well as bolstering programs that assist states secure deals on sickle-cell medications in Medicaid, the fact sheet said. 

The order also requires DHS to seek comment on the Medicare Drug Price Negotiation Program, which the Biden administration authorized under the Inflation Reduction Act and allows Medicare to directly engage in hashing out prescription prices with drug companies. 

‘The guidance shall improve the transparency of the Medicare Drug Price Negotiation Program, prioritize the selection of prescription drugs with high costs to the Medicare program, and minimize any negative impacts of the maximum fair price on pharmaceutical innovation within the United States,’ the order said. 

Drug prices have significantly ramped up in recent years. Between January 2022 and January 2023, prescription drug prices rose more than 15% and reached an average of $590 per drug product, according to the Department of Health and Human Services. Of the 4,200 prescription drugs included on that list, 46% of the price increases exceeded the rate of inflation. 

Previous efforts under the first Trump administration to curb prescription drug prices included installing a cap on Medicaid prescription drug plans for insulin at $35. 

Meanwhile, Trump’s 145% tariffs on Chinese imports to the U.S. could mean that healthcare costs are particularly susceptible to price increases. Market research group Black Book Research found that 84% of experts predict that prices for medical treatments and drugs will rise due to the tariffs, according to a survey released in February. 

Additionally, Trump signaled Monday that tariffs on the pharmaceutical were headed down the pipeline. 

‘We don’t make our own drugs anymore,’ Trump told reporters Monday. ‘The drug companies are in Ireland, and they’re in lots of other places, China.’

Trump signed the executive order Tuesday, along with others that seek to prevent illegal immigrants from accessing Social Security benefits, and another one calling to investigate the impact of imported processed mineral on national security. 

Tuesday’s executive order comes days after the Department of Health and Human Services’ Centers for Medicare and Medicaid Services told states Thursday that the federal government would cease assistance to states to fund nonmedical services geared toward things like nutrition for those enrolled in Medicaid. 

Fox News’ Alec Schemmel contributed to this report. 

This post appeared first on FOX NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream
next post
Top Hegseth advisor Dan Caldwell placed on administrative leave by Defense Department

Related Posts

Trump calls Biden’s cancer diagnosis ‘very sad’ while...

May 20, 2025

With Trump’s backing Israel pushes deeper into Gaza...

April 13, 2025

Biden-Harris admin treatment of Ukraine, Israel wars ‘differs...

November 4, 2024

John Bolton compares Kash Patel to Stalin’s right-hand...

December 2, 2024

Israeli Prime Minister Netanyahu criticizes military’s plans for...

June 17, 2024

Johnson allies urge Trump to intervene as messy...

December 24, 2024

Speaker Johnson rips ‘lack of leadership’ in Biden...

October 5, 2024

MAGAfest Destiny? Trump flexes his muscles with repeated...

January 9, 2025

House Ethics Committee to meet with vote on...

December 5, 2024

Trump courts Libertarians to draw party activists away...

May 26, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Analyzing SIL, USO, and NVDA: Could These Bullish Patterns Trigger?

      May 30, 2025
    • Nuclear Power Trio: OKLO, SMR, and CCJ in Focus

      May 30, 2025
    • White House discloses who will lead DOGE efforts after Musk’s departure

      May 30, 2025
    • Lone Biden official breaks silence on cognitive decline as Cabinet stays mute

      May 30, 2025
    • Hawley urges DOJ probe of Chinese trucking company

      May 30, 2025

    Categories

    • Business (955)
    • Investing (2,274)
    • Politics (2,820)
    • Stocks (1,042)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved